The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.

Ghada Kchour 1 Sa Rezaee 2 Reza Farid 3 Akram Ghantous 4 Houshang Rafatpanah 3 Mahdi Tarhini 5 Mohamad-Mehdi Kooshyar 6 Hiba El Hajj 7 Fadwa Berry 1 Mohamad Mortada 1 Roudaina Nasser 3 Abbas Shirdel 3 Zeina Dassouki 3 Mohamad Ezzedine 1 Hossein Rahimi 3 Ardeshir Ghavamzadeh 8 Hugues De Thé 9 Olivier Hermine 10 Mahmoud Mahmoudi 3, * Ali Bazarbachi 3, *
* Auteur correspondant
1 Department of Biology
2 Microbiology and Virology Research Center
3 Immunology Research Centre Bu-Ali Research Institute
4 LAU - Lebanese American University
5 Faculty of Nursing Sciences
6 Department of Internal Medicine [Mashhad]
7 Department of Internal Medicine
8 Hematology-Oncology and Stem Cell Research Center
9 Pathologie et virologie moléculaire
10 CHRI - Cytokines, hématopoïèse et réponse immune
Abstract : BACKGROUND: HTLV-I associated adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis due to chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN. RESULTS: Here we assessed Th1/Th2/Treg cytokine gene expression profiles in 16 ATL patients before and 30 days after treatment with arsenic/IFN/zidovudine, in comparison with HTLV-I healthy carriers and sero-negative blood donors. ATL patients at diagnosis displayed a Treg/Th2 cytokine profile with significantly elevated transcript levels of Foxp3, interleukin-10 (IL-10), and IL-4 and had a reduced Th1 profile evidenced by decreased transcript levels of interferon-γ (IFN-γ) and IL-2. Most patients (15/16) responded, with CD4+CD25+ cells significantly decreasing after therapy, paralleled by decreases in Foxp3 transcript. Importantly, arsenic/IFN/zidovudine therapy sharply diminished IL-10 transcript and serum levels concomittant with decrease in IL-4 and increases in IFN-γ and IL-2 mRNA, whether or not values were adjusted to the percentage of CD4+CD25+ cells. Finally, IL-10 transcript level negatively correlated with clinical response at Day 30. CONCLUSIONS: The observed shift from a Treg/Th2 phenotype before treatment toward a Th1 phenotype after treatment with arsenic/IFN/zidovudine may play an important role in restoring an immuno-competent micro-environment, which enhances the eradication of ATL cells and the prevention of opportunistic infections.
Keywords : Arsenic Interferon Zidovudine HTLV-I ATL Cytokines Immune deficiency
Type de document :
Article dans une revue
Retrovirology, BioMed Central, 2013, 10 (1), pp.91. 〈10.1186/1742-4690-10-91〉
Liste complète des métadonnées

Littérature citée [54 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00868737
Contributeur : Ed. Bmc <>
Soumis le : mardi 1 octobre 2013 - 21:10:32
Dernière modification le : vendredi 27 juillet 2018 - 11:16:03
Document(s) archivé(s) le : lundi 6 janvier 2014 - 09:36:35

Fichiers

1742-4690-10-91.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

UNIV-PARIS5 | USPC

Citation

Ghada Kchour, Sa Rezaee, Reza Farid, Akram Ghantous, Houshang Rafatpanah, et al.. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.. Retrovirology, BioMed Central, 2013, 10 (1), pp.91. 〈10.1186/1742-4690-10-91〉. 〈inserm-00868737〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

678

Téléchargements de fichiers

297

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD